Additionally, loss-of-function alterations in RB1, predicted to contribute to CDK4/6 inhibitor resistance [48], were observed in 13.3% (6/56) of CDK4/6 inhibitor-treated HR+ HER2- breast cancer patients. Here, ERBB2 is linked to breast cancer.